[go: up one dir, main page]

NO20064771L - 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer - Google Patents

2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer

Info

Publication number
NO20064771L
NO20064771L NO20064771A NO20064771A NO20064771L NO 20064771 L NO20064771 L NO 20064771L NO 20064771 A NO20064771 A NO 20064771A NO 20064771 A NO20064771 A NO 20064771A NO 20064771 L NO20064771 L NO 20064771L
Authority
NO
Norway
Prior art keywords
alk5
pyridyl substituted
substituted imidazoles
alk4
inhibitors
Prior art date
Application number
NO20064771A
Other languages
English (en)
Inventor
Dae-Kee Kim
Yung-Jue Bang
Hun-Taek Kim
Il-Sang Cho
Myoung-Soon Park
Young Jae An
Joon Hun Choi
Original Assignee
Ewha Univ Collaboration Founda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Univ Collaboration Founda filed Critical Ewha Univ Collaboration Founda
Publication of NO20064771L publication Critical patent/NO20064771L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)

Abstract

Foreliggende oppfinnelse angår 2-pyridyl substituerte imidazoler som er inhibitorer for den transformerende vekst-faktor P (TGF-P) type 1 reseptoren (ALK5) og/eller activin type I reseptoren (ALK4), framgangsmåter for framstilling av disse, og deres bruk innen medisin, særlig innen behandling og forbygging av en sykdomstilstand som formidles av disse reseptorene.
NO20064771A 2004-04-21 2006-10-19 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer NO20064771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040027591A KR100749566B1 (ko) 2004-04-21 2004-04-21 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
PCT/KR2004/002891 WO2005103028A1 (en) 2004-04-21 2004-11-09 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors

Publications (1)

Publication Number Publication Date
NO20064771L true NO20064771L (no) 2007-01-19

Family

ID=35196912

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064771A NO20064771L (no) 2004-04-21 2006-10-19 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer

Country Status (14)

Country Link
US (1) US7407958B2 (no)
EP (1) EP1620426A1 (no)
JP (1) JP4678540B2 (no)
KR (1) KR100749566B1 (no)
CN (1) CN1972921B (no)
AU (1) AU2004318777B2 (no)
BR (1) BRPI0418765B8 (no)
CA (1) CA2564442C (no)
IL (1) IL178757A (no)
MX (1) MXPA06012096A (no)
NO (1) NO20064771L (no)
RU (1) RU2348626C2 (no)
WO (1) WO2005103028A1 (no)
ZA (1) ZA200609626B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420685B2 (en) * 2004-04-21 2013-04-16 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US20080319012A1 (en) * 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8410146B2 (en) * 2004-04-21 2013-04-02 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
CN102015686B (zh) 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2299812B1 (en) * 2008-05-27 2017-07-12 Yale University Targeting tgf-beta as a therapy for alzheimer's disease
WO2009146408A1 (en) * 2008-05-30 2009-12-03 Summa Health Systems Llc Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
RU2475243C1 (ru) * 2012-02-16 2013-02-20 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Средство, обладающее антигипертензивной активностью
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN112266378B (zh) * 2020-11-09 2021-10-12 延边大学 含吲唑结构的咪唑类衍生物及其制备方法和应用
US12240830B2 (en) * 2021-08-13 2025-03-04 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN115747214B (zh) * 2022-07-12 2025-11-18 安徽理工大学 Mlph基因在制备治疗尘肺病药物中的应用
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DK0786455T3 (da) * 1994-09-26 2004-03-29 Shionogi & Co Imidazolderivater
PL191111B1 (pl) * 1997-04-24 2006-03-31 Ortho Mcneil Pharm Inc Podstawione imidazole, sposób ich wytwarzania, kompozycje zawierające podstawione imidazole oraz ich zastosowanie
DE60001229T2 (de) * 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JPWO2002096875A1 (ja) 2001-05-25 2004-09-09 持田製薬株式会社 鎮痛作用を有する４−ヒドロキシピペリジン誘導体
JP2003040888A (ja) * 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
GB0218079D0 (en) * 2002-08-03 2002-09-11 Boatman Peter J A pipe and pipe assembly
WO2004026859A1 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators

Also Published As

Publication number Publication date
IL178757A0 (en) 2007-02-11
EP1620426A1 (en) 2006-02-01
RU2006140989A (ru) 2008-05-27
WO2005103028A1 (en) 2005-11-03
RU2348626C2 (ru) 2009-03-10
CA2564442C (en) 2011-06-14
ZA200609626B (en) 2008-08-27
US20050261299A1 (en) 2005-11-24
CA2564442A1 (en) 2005-11-03
KR100749566B1 (ko) 2007-08-16
KR20050102752A (ko) 2005-10-27
CN1972921B (zh) 2012-01-04
BRPI0418765B8 (pt) 2021-05-25
JP2007533734A (ja) 2007-11-22
JP4678540B2 (ja) 2011-04-27
AU2004318777B2 (en) 2008-10-16
US7407958B2 (en) 2008-08-05
BRPI0418765B1 (pt) 2019-06-04
IL178757A (en) 2011-08-31
AU2004318777A1 (en) 2005-11-03
BRPI0418765A (pt) 2007-10-09
MXPA06012096A (es) 2007-11-20
CN1972921A (zh) 2007-05-30

Similar Documents

Publication Publication Date Title
NO20064771L (no) 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer
UA106136C2 (uk) 2-піридилзаміщені імідазоли як терапевтичні інгібітори alk5 і/або alk4
DE602007004750D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20064015L (no) Kondenserte derivater av pyrazol
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
DK2175859T3 (da) Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20051985L (no) Indazoler, benzotiazoler og benzoisotiazoler, samt fremstilling og anvendelser derav.
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2013009140A3 (en) 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
NO20083406L (no) FGF-reseptorer for dimere forbindelser
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20065622L (no) H-indazoler, benzotiazoler, 1,2-benzoisoksazoler, 1,2-benzoisotiazoler og kromoner, og fremstilling og anvendelser derav.
JO2645B1 (en) Vehicles
NO20074414L (no) 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application